Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials

Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis

(2018) E Dokoupilová et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study

(2017) Francisco J. Blanco et al.   Arthritis & Rheumatology

Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study

(2016) W. Tlustochowicz et al.   JOURNAL OF RHEUMATOLOGY

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association ofHLA-DRB1alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis

(2015) Gerd R. Burmester et al.   RHEUMATOLOGY

Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials

(2015) Young Ho Lee et al.   RHEUMATOLOGY INTERNATIONAL

Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

(2014) Vibeke Strand et al.   Health and Quality of Life Outcomes

Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA)

(2014) John Maringwa et al.   JOURNAL OF CLINICAL PHARMACOLOGY

One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study

(2014) M. C. Genovese et al.   JOURNAL OF RHEUMATOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

(2014) Mark C. Genovese et al.   Arthritis & Rheumatology

Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential

(2013) Herbert Kellner   Therapeutic Advances in Musculoskeletal Disease

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

(2012) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of Th17 cells in human autoimmune arthritis

(2010) Jan Leipe et al.   ARTHRITIS AND RHEUMATISM

Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors

(2010) Devesh Mewar et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis

(2010) Steven S. Storage et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

IL-17 as a future therapeutic target for rheumatoid arthritis

(2009) Wim B. van den Berg et al.   Nature Reviews Rheumatology